BiotechTube
PARI Pharma

PARI Pharma

Starnberg, Germany· Est.
pari.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

PARI Pharma is a long-established, privately-held German company that has evolved into a leading partner for inhaled drug development, leveraging its proprietary eFlow mesh nebulizer technology. It operates as a contract development and manufacturing organization (CDMO) for respiratory therapeutics, offering end-to-end support from device customization to regulatory strategy and commercial supply. With over 20 years of experience in mesh nebulization, PARI supports a robust pipeline of partner programs, including several in late-stage clinical trials, targeting complex respiratory diseases like non-CF bronchiectasis, pulmonary fibrosis, and bronchiolitis obliterans syndrome.

Respiratory

Technology Platform

eFlow Technology: A proprietary, high-performance vibrating mesh nebulizer platform enabling rapid, efficient, and customizable aerosol delivery of complex drug formulations for deep lung deposition.

Opportunities

The growing pipeline of inhaled biologics and complex molecules for respiratory disease creates sustained demand for high-performance nebulizer technology.
Expansion into digital connected health features offers a pathway to differentiate its platform and improve patient outcomes.
Successful commercialization of multiple late-stage partner programs can drive significant recurring manufacturing revenue.

Risk Factors

Revenue is dependent on the clinical and regulatory success of partners' drug candidates, creating significant pipeline risk.
The company faces competition from other advanced nebulizer and dry powder inhaler technologies.
As a critical supplier for regulated combination products, it bears substantial regulatory and manufacturing quality risk that could disrupt multiple partner programs.

Competitive Landscape

PARI competes with other specialized drug delivery CDMOs and device companies offering nebulizer technologies, such as Philips (Respironics), Vectura (part of CSL), and Aerogen. Its primary competitive advantage is its deep, 20+ year focus on mesh nebulization, a broad, customizable platform, and end-to-end regulatory and manufacturing support. Competition also comes from developers of next-generation DPIs and soft mist inhalers for suitable drug formulations.

More companies in Drug Delivery & Formulation →More companies in Germany →